MDM Group, Inc. announces world commercialization rights to breakthrough diagnostics
DALLAS, Texas, Feb. 22 /CNW/ - MDM Group, Inc. (OTCBB ''MDDM'') today
announced the entering into of preliminary agreements with its Investment
Banker, Select Corporate Services, Inc. and S & S Biophysics Laboratory Pty.
Ltd. (''Laboratory''). These agreements provide for MDDM to have the joint
World commercialization rights to the Dielectric Diagnostic Analyzer (''DDA'')
developed by the Laboratory.
The DDA is the result of over 12 years of work by the Laboratory and is
the only instrument of its kind in the World. The DDA represents a major new
technological breakthrough in the early detection of viral diseases, including
cancer. DDA aims to bring a new dimension of accuracy, versatility and
sensitivity to the measurement of dielectric characteristics of living tissue.
The technology is based on the discovery by the directors of the
Laboratory that the viral invasion causes dielectric polarization of living
cells long before disease appearance clinically (lump or tumor), and before
biochemical transformations.
The dielectric properties of cells transformed to a pre-cancerous stage
are detectable by specifically designed dielectric measurements developed by
the Laboratory. The earlier a viral disease is detected the more likely it is
to respond to treatment.
Features of the DDA technique
- Cancer detection becomes possible at the early stages of induction,
before its clinical appearance. In the world of medical technology no
such method exists at present.
- The method simultaneously measures several different dielectric
parameters. This ensures that the information obtained is reliable and
self-checking. It is well known that due to metabolic activity, cell
morphology is continuously changing. In the case of the DDA method,
all the measured parameters respond to the same intracellular
morphology.
- Tests are harmless, painless, non-invasive and 100% accurate when
performed by qualified professional people.
- Tests are autonomous and independent of a patient's emotional and
physical condition.
- The technology has been developed to the point where the DDA
prototypes can be assembled from today to provide routine and
inexpensive in-vitro testing.
- An inexpensive data capture unit can be linked electronically to a
central DDA processor, thus providing the capability for mass
screening of the public at an economical cost.
Company President, Mr. Peter Boonen, today stated: ''This agreement today
is the culmination of many months of negotiation. The DDA, we believe, is a
major scientific breakthrough in that it makes early detection of cancer
possible well before its clinical appearance. The DDA technology represents a
perfect fit for MDDM and is expected to be a significant compliment to the
Company's commercialization rights to the cancer treatment products, currently
under development. We now aim to position MDDM at the world forefront of
cancer diagnostics as well as ultimately cancer treatment.''
Note: The information contained in this release, other than historical
information, may be considered forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Projections and other
forward-looking statements and management expectations regarding future events
and/or financial performance of the company - although given in good faith -
are inherently uncertain and actual events or results may differ materially.
-30-
|
